Jeong Mo Bae1, Tae Hun Lee1, Nam-Yun Cho1, Tae-You Kim1, Gyeong Hoon Kang1. 1. Jeong Mo Bae, Tae Hun Lee, Nam-Yun Cho, Gyeong Hoon Kang, Laboratory of Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, South Korea.
Abstract
AIM: To investigate the clinicopathologic characteristics and prognostic implications associated with loss of CDX2 expression in colorectal cancers (CRCs). METHODS: We immunohistochemically evaluated CDX2 expression in 713 CRCs and paired our findings to clinicopathologic and molecular characteristics of each individual. Endpoints included cytokeratin 7 and CK20 expression, microsatellite instability, CpG island methylator phenotype, and KRAS and BRAF mutation statuses. Univariate and multivariate survival analysis was performed to reveal the prognostic value of CDX2 downregulation. RESULTS: CDX2 expression was lost in 42 (5.9%) patients. Moreover, loss of CDX2 expression was associated with proximal location, infiltrative growth, advanced T, N, M and overall stage. On microscopic examination, loss of CDX2 expression was associated with poor differentiation, increased number of tumor-infiltrating lymphocytes, luminal serration and mucin production. Loss of CDX2 expression was also associated with increased CK7 expression, decreased CK20 expression, CpG island methylator phenotype, microsatellite instability and BRAF mutation. In a univariate survival analysis, patients with loss of CDX2 expression showed worse overall survival (P < 0.001) and progression-free survival (P < 0.001). In a multivariate survival analysis, loss of CDX2 expression was an independent poor prognostic factor of overall survival [hazard ratio (HR) = 1.72, 95%CI: 1.04-2.85, P = 0.034] and progression-free survival (HR = 1.94, 95%CI: 1.22-3.07, P = 0.005). CONCLUSION: Loss of CDX2 expression is associated with aggressive clinical behavior and can be used as a prognostic marker in CRCs.
AIM: To investigate the clinicopathologic characteristics and prognostic implications associated with loss of CDX2 expression in colorectal cancers (CRCs). METHODS: We immunohistochemically evaluated CDX2 expression in 713 CRCs and paired our findings to clinicopathologic and molecular characteristics of each individual. Endpoints included cytokeratin 7 and CK20 expression, microsatellite instability, CpG island methylator phenotype, and KRAS and BRAF mutation statuses. Univariate and multivariate survival analysis was performed to reveal the prognostic value of CDX2 downregulation. RESULTS:CDX2 expression was lost in 42 (5.9%) patients. Moreover, loss of CDX2 expression was associated with proximal location, infiltrative growth, advanced T, N, M and overall stage. On microscopic examination, loss of CDX2 expression was associated with poor differentiation, increased number of tumor-infiltrating lymphocytes, luminal serration and mucin production. Loss of CDX2 expression was also associated with increased CK7 expression, decreased CK20 expression, CpG island methylator phenotype, microsatellite instability and BRAF mutation. In a univariate survival analysis, patients with loss of CDX2 expression showed worse overall survival (P < 0.001) and progression-free survival (P < 0.001). In a multivariate survival analysis, loss of CDX2 expression was an independent poor prognostic factor of overall survival [hazard ratio (HR) = 1.72, 95%CI: 1.04-2.85, P = 0.034] and progression-free survival (HR = 1.94, 95%CI: 1.22-3.07, P = 0.005). CONCLUSION: Loss of CDX2 expression is associated with aggressive clinical behavior and can be used as a prognostic marker in CRCs.
Authors: Kyu-Won Jung; Young-Joo Won; Hyun-Joo Kong; Chang-Mo Oh; Duk Hyoung Lee; Jin Soo Lee Journal: Cancer Res Treat Date: 2014-04-22 Impact factor: 4.679
Authors: Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs Journal: Gut Date: 2008-10-02 Impact factor: 23.059
Authors: Y Y Juo; F M Johnston; D Y Zhang; H H Juo; H Wang; E P Pappou; T Yu; H Easwaran; S Baylin; M van Engeland; N Ahuja Journal: Ann Oncol Date: 2014-04-08 Impact factor: 32.976
Authors: C Bonhomme; I Duluc; E Martin; K Chawengsaksophak; M-P Chenard; M Kedinger; F Beck; J-N Freund; C Domon-Dell Journal: Gut Date: 2003-10 Impact factor: 23.059
Authors: Dallas R English; Joanne P Young; Julie A Simpson; Mark A Jenkins; Melissa C Southey; Michael D Walsh; Daniel D Buchanan; Melissa A Barker; Andrew M Haydon; Simon G Royce; Aedan Roberts; Susan Parry; John L Hopper; Jeremy J Jass; Graham G Giles Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-07 Impact factor: 4.254
Authors: James Saller; Sameer Al Diffalha; Kevin Neill; Rahill A Bhaskar; Cecilia Oliveri; David Boulware; Henry Levine; Isaac Kalvaria; F Scott Corbett; Arun Khazanchi; Jason Klapman; Domenico Coppola Journal: Dig Dis Sci Date: 2019-11-05 Impact factor: 3.199
Authors: Tessa P Sandberg; Iris Sweere; Gabi W van Pelt; Hein Putter; Louis Vermeulen; Peter J Kuppen; Rob A E M Tollenaar; Wilma E Mesker Journal: Cell Oncol (Dordr) Date: 2019-03-08 Impact factor: 6.730
Authors: Piero Dalerba; Debashis Sahoo; Soonmyung Paik; Xiangqian Guo; Greg Yothers; Nan Song; Nate Wilcox-Fogel; Erna Forgó; Pradeep S Rajendran; Stephen P Miranda; Shigeo Hisamori; Jacqueline Hutchison; Tomer Kalisky; Dalong Qian; Norman Wolmark; George A Fisher; Matt van de Rijn; Michael F Clarke Journal: N Engl J Med Date: 2016-01-21 Impact factor: 91.245